Liver-Directed PAH Expression Cassette for PKU Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for phenylketonuria (PKU), such as dietary restrictions and enzyme substitution therapies, are inadequate in maintaining stable blood phenylalanine levels and addressing cognitive and neuropsychiatric issues in patients, even with good adherence to treatment protocols.
Innovation Solution
Development of an expression cassette that encodes phenylalanine hydroxylase (PAH) for use in recombinant adeno-associated virus (rAAV) vectors, which are designed to efficiently transfer and express the PAH gene in liver cells, thereby restoring PAH activity and reducing blood phenylalanine levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dietary restriction and enzyme substitution therapy are used to treat PKU, then blood phenylalanine levels can be reduced, but cognitive and neuropsychiatric issues persist and blood levels become unstable
Solution Approach 1:
The patent uses liver-specific promoters (ALB, AAT, HFE) as intermediaries to drive PAH gene expression specifically in hepatocytes. This mediator approach ensures that PAH enzyme is produced where it is needed (liver) to maintain stable blood Phe levels, rather than relying on external dietary restrictions that are difficult to maintain consistently.
Solution Approach 2:
The gene therapy approach enables the liver cells themselves to produce functional PAH enzyme through the introduced transgene. The liver essentially serves itself by regenerating the missing enzymatic function, creating stable endogenous Phe metabolism without requiring continuous external intervention like dietary restrictions.
2Object-affected harmful factors
If dietary restriction is enforced to maintain low blood phenylalanine levels, then neurotoxicity is reduced, but patient compliance deteriorates over time
Solution Approach 1:
The gene therapy approach enables the liver cells themselves to produce functional PAH enzyme through the introduced transgene. The liver essentially serves itself by regenerating the missing enzymatic function, creating stable endogenous Phe metabolism without requiring continuous external intervention like dietary restrictions.
Solution Approach 2:
The liver-specific promoters (ALB, AAT, HFE) act as intermediaries that automatically regulate PAH expression in hepatocytes, replacing the need for patient self-monitoring and dietary management. This intermediary system provides automatic, stable control of blood Phe levels.
3Object-affected harmful factors
If enzyme substitution therapy is used to lower blood phenylalanine levels, then acute toxicity is reduced, but long-term neurological outcomes remain poor
Solution Approach 1:
The patent uses liver-specific promoters (ALB, AAT, HFE) as intermediaries to drive PAH gene expression specifically in hepatocytes. This mediator approach ensures that PAH enzyme is produced where it is needed (liver) to maintain stable blood Phe levels, rather than relying on external dietary restrictions that are difficult to maintain consistently.
Solution Approach 2:
The gene therapy approach enables the liver cells themselves to produce functional PAH enzyme through the introduced transgene. The liver essentially serves itself by regenerating the missing enzymatic function, creating stable endogenous Phe metabolism without requiring continuous external intervention like dietary restrictions.
Data Source
AI summary
Provided herein are expression cassettes for expressing a transgene in a liver cell, wherein the transgene encodes a PAH polypeptide. Also provided are methods to treat phenylketonuria (PKU) and/or to reduce levels of phenylalanine in an individual in need thereof. Further provided herein are vectors (e.g., rAAV vectors), viral particles, pharmaceutical compositions and kits for expressing a PAH polypeptide in an individual in need thereof.